Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -177.35% is 168% below its 5-year average of -66.28%, near the low end of its 5-year range (-177.35%–-23.35%).
As of the fiscal period ended Tuesday, June 30, 2026. 39.95% below its 12-month average of -126.73%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -177.35%.
RETURN ON EQUITY (ROE)
-177.35%
RETURN ON EQUITY (ROE) AVG TTM
-126.73%
RETURN ON EQUITY (ROE) AVG 3Y
-85.92%
RETURN ON EQUITY (ROE) AVG 5Y
-66.28%
RETURN ON EQUITY (ROE) AVG 10Y
-51.28%
RETURN ON EQUITY (ROE) AVG 15Y
-66.81%
RETURN ON EQUITY (ROE) AVG 20Y
-66.97%
CURRENT VS TTM AVG
-39.95%
CURRENT VS 3Y AVG
-106.42%
CURRENT VS 5Y AVG
-167.56%
CURRENT VS 10Y AVG
-245.82%
CURRENT VS 15Y AVG
-165.46%
CURRENT VS 20Y AVG
-164.83%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-322.17%
vs the sector median at left
Lisata Therapeutics, Inc.
Market Cap
$11.29M
Return on Equity (ROE)
-177.35%
TTM Avg
-126.73%
3Y Avg
-85.92%
5Y Avg
-66.28%
Market Cap
$11.19M
Return on Equity (ROE)
-276.21%
TTM Avg
-134.62%
3Y Avg
-196.35%
5Y Avg
-146.45%
Market Cap
$10.94M
Return on Equity (ROE)
-477.54%
TTM Avg
-207.60%
3Y Avg
64.51%
5Y Avg
-22.91%
Market Cap
$11.33M
Return on Equity (ROE)
N/A
TTM Avg
216.74%
3Y Avg
-5384.23%
5Y Avg
-3626.91%
Market Cap
$11.00M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
Market Cap
$11.38M
Return on Equity (ROE)
-102.40%
TTM Avg
-97.28%
3Y Avg
-110.13%
5Y Avg
-94.77%
Market Cap
$11.39M
Return on Equity (ROE)
-65.18%
TTM Avg
-26.62%
3Y Avg
-94.28%
5Y Avg
-90.35%
Market Cap
$11.01M
Return on Equity (ROE)
-214.92%
TTM Avg
-46.13%
3Y Avg
-156.76%
5Y Avg
-652.77%
Market Cap
$10.83M
Return on Equity (ROE)
N/A
TTM Avg
-22.56%
3Y Avg
-244.57%
5Y Avg
3710.91%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lisata Therapeutics, Inc. (LSTA) | $11.29M | -177.35% | -126.73% | -85.92% | -66.28% |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.19M | -276.21% | -134.62% | -196.35% | -146.45% |
| Cerenome, Inc. (CNSY)vs › | $10.94M | -477.54% | -207.60% | 64.51% | -22.91% |
| Pluri Inc. (PLUR)vs › | $11.33M | N/A | 216.74% | -5384.23% | -3626.91% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | -43.97% | -160.70% | -188.29% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.38M | -102.40% | -97.28% | -110.13% | -94.77% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.39M | -65.18% | -26.62% | -94.28% | -90.35% |
| BioVie Inc. (BIVI)vs › | $11.01M | -214.92% | -46.13% | -156.76% | -652.77% |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | -22.56% | -244.57% | 3710.91% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | -37052.06% | -237.80% | -258.91% | -310.30% |
ROE
-177.4%
ROA
-132.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -177.35% |
| 2026-03-31 | -149.65% |
| 2025-12-31 | -111.65% |
| 2025-09-30 | -105.00% |
| 2025-06-30 | -89.99% |
| 2025-03-31 | -76.15% |
| 2024-12-31 | -67.58% |
| 2024-09-30 | -61.56% |
| 2024-06-30 | -55.09% |
| 2024-03-31 | -46.64% |
| 2023-12-31 | -43.28% |
| 2023-09-30 | -40.53% |
| 2023-06-30 | -92.44% |
| 2023-03-31 | -92.17% |
| 2022-12-31 | -81.45% |
| 2022-09-30 | -76.40% |
| 2022-06-30 | -29.82% |
| 2022-03-31 | -26.70% |
| 2021-12-31 | -29.77% |
| 2021-09-30 | -26.46% |
| 2021-06-30 | -23.35% |
| 2021-03-31 | -11.08% |
| 2020-12-31 | -25.08% |
| 2020-09-30 | -20.34% |
| 2020-06-30 | -21.43% |
| 2020-03-31 | -110.10% |
| 2019-12-31 | -93.01% |
| 2019-09-30 | -71.15% |
| 2019-06-30 | -55.59% |
| 2019-03-31 | -44.78% |
| 2018-12-31 | -42.85% |
| 2018-09-30 | -37.66% |
| 2018-06-30 | -35.09% |
| 2018-03-31 | 60.20% |
| 2017-12-31 | 45.67% |
| 2017-09-30 | 37.45% |
| 2017-06-30 | 30.35% |
| 2016-12-31 | -668.67% |
| 2016-09-30 | -557.38% |
| 2016-03-31 | -539.32% |
| 2015-12-31 | -341.10% |
| 2015-09-30 | -106.98% |
| 2015-06-30 | -97.77% |
| 2015-03-31 | -119.79% |
| 2014-12-31 | -93.78% |
| 2014-09-30 | -88.56% |
| 2014-06-30 | -61.37% |
| 2014-03-31 | -73.54% |
| 2013-12-31 | -62.33% |
| 2013-09-30 | -117.51% |
| 2013-06-30 | -123.40% |
| 2013-03-31 | -180.87% |
| 2012-12-31 | -162.07% |
| 2012-09-30 | -118.46% |
| 2012-06-30 | -120.91% |
| 2012-03-31 | -72.82% |
| 2011-12-31 | -75.73% |
| 2011-09-30 | -46.63% |
| 2011-06-30 | -54.55% |
| 2011-03-31 | -44.41% |
| 2010-12-31 | -47.89% |
| 2010-09-30 | -62.71% |
| 2010-06-30 | -60.04% |
| 2010-03-31 | -93.60% |
| 2009-12-31 | -101.91% |
| 2009-06-30 | -287.54% |
| 2008-09-30 | -500.28% |
| 2008-06-30 | -667.44% |
| 2008-03-31 | -527.66% |
| 2007-12-31 | -314.98% |
| 2007-09-30 | -244.97% |
| 2007-03-31 | -494.36% |
| 2006-09-30 | -340.66% |
